Valsartan-Containing Drug Manufacturer Seeks Exclusion of Consultant’s Report

CAMDEN, N.J. — Two defendants in the MDL for valsartan-containing drugs (VCDs) has asked a New Jersey federal judge to exclude a consultant’s report regarding their investigations of out-of-specification results affecting non-Valsartan products, arguing it has no relevance.

In a Feb. 16 motion filed before Judge Robert B. Kugler of the U.S. District Court for the District of New Jersey, Torrent Pharmaceuticals Ltd. and Torrent Pharma Inc. argue that “audit findings unrelated to VCDs do not ‘have any tendency to make a fact of consequence in this action more or less probable,’ and should therefore be excluded.”

Torrent adds …